StemCell Therapy

Researchers from several Russian institutes, including MIPT, have found out how prolonged exposure to ionizing radiation affects human stem cells. They discovered that it causes a cell cycle delay, which leads to faster repairs of radiation-induced DNA double-strand breaks, with fewer errors. It is unclear what the health implications are, particularly how this affects the risk of developing cancer.

When statistics is no good

To a physicist, an ordinary flashlight or a portable radio is, among other things, radiation sources, and ionizing radiation is the proper scientific name of the high-energy rays that an ordinary person thinks of when they hear the word radiation. It comes in different types, including X-rays, gamma rays, and streams of various particles. Ionizing radiation is capable of turning neutral atoms and molecules into charged ions. The human body is inevitably exposed to radiation, with an average person receiving about 3 milligrays of natural background radiation annually. Moreover, one X-ray exam amounts to anywhere from 0.001 to 10 milligrays of additional exposure, depending on the exact procedure. That said, overexposure is dangerous: A dose of more than 1,000 milligrays received within a brief period of time causes acute radiation sickness.

To ensure radiation security, it is vital that we can accurately assess the risks posed by ionizing radiation. Studies of people that were exposed to radiation have only conclusively established the increased risk of cancer as a result of receiving a high dose of radiation. This led the regulating authorities to accept a linear model, under which low doses of radiation, too, increase the risk of cancer. However, experiments showed that low-dose radiation exposure either had no adverse biological effect or even was beneficial, as evidenced by prolonged life spans and less frequent cancer occurrence. Apart from that, the importance of the so-called dose rate should not be overlooked. Exposure to equal doses of radiation over shorter or longer time intervals has a different effect, with slow irradiation causing less harm. The extent to which dose rate affects the biological outcomes has been a cause of much debate. Because in a real-life setting, people are more likely to face prolonged exposure to low-dose radiation, it is crucial that we understand its effects.

DNA double-strand breaks

One of the negative effects of radiation is the formation of the so-called DNA double-strand breaks, in which both strands of the double helix are severed. Fortunately, the cell is capable of repairing damaged DNA. If one of the two strands is damaged, the other can be used to reverse this. However, in the case of a double-strand break, other more error-prone mechanisms have to be employed. Left unrepaired or misrepaired, such lesions can give rise to oncological diseases. This explains why research into the effects of radiation on living cells tends to focus on double-strand breaks. Not long ago, it was found that stem cells functionally undifferentiated cells play a major part in the formation of tumors by accumulating mutations and passing them on to the specialized cells that are their descendants. However, stem cell response to prolonged irradiation remains poorly understood.

The scientists conducted several experiments using stem cells derived from gingivae, or the gums. They treated the cells with identical radiation doses administered over long and short time spans. The formation of double-strand breaks was monitored using stained H2AX and 53BP1 proteins as markers. With brief but intense radiation exposure, the incidence of both markers was found to increase linearly with the dose. But in the case of prolonged irradiation, the response was linear only up to a certain point, followed by a plateau at 1,000 milligrays. In other words, after reaching a certain number, the lesion count does not continue to rise. A balance of sorts is achieved between break formation and repair.

DNA repair

The cell comes equipped with repair systems capable of mending DNA double-strand breaks. However, following intense irradiation, the cell has to resort to a mechanism known as end joining a quick but faulty procedure in eight out of 10 double-strand breaks. This often leads to chromosomal aberrations. Such misrepairs of DNA breaks can potentially result in cell death, oncogene activation, and anti-oncogene suppression. But there is an alternative mechanism of DNA repair, called homologous recombination. It uses a similar or identical DNA molecule as a template and produces much fewer errors, but it is only available during certain phases of the cell cycle. The researchers monitored homologous recombination using Rad51, another protein marker. During a two-hour long exposure, the amount of Rad51 remained roughly constant, followed by a linear growth afterward. The team hypothesized that prolonged irradiation might activate homologous recombination.

Cell division

Stem cells can be divided into two groups, called proliferating and quiescent, where the former undergo division and the latter have ceased reproducing, and there is a balance between the two types of cells. The researchers counted up the DNA double-strand breaks in proliferating and quiescent cells separately. This is made possible by a certain protein that is only found in cells undergoing division. It turned out, in both types of cells, the number of DNA breaks grew, eventually reaching a constant value.

It was also observed that exposure to radiation did not change the roughly 4-1 ratio between proliferating and quiescent cells. However, a more detailed investigation revealed that four hours of slow irradiation result in a considerably increased number of cells in the S and G2 phases of the cycle, that is DNA synthesis and final preparation for division, respectively. It is during these phases that a copy of the cells DNA is available for the sake of division, but also to be used as a template in homologous recombination. This fact is a likely explanation for the detection of increased amounts of the Rad51 marker. To put it another way, irradiation causes a delay in the cell cycle with the consequence that, at any given time, there are more cells in those phases which enable homologous recombination. This means it is possible to repair DNA double-strand breaks correctly.

We have shown that prolonged irradiation of mesenchymal stem cells leads to cell cycle redistribution. This might influence the biological response to radiation, says Sergey Leonov, the director of the Phystech School of Biological and Medical Physics. Our findings could become the basis of further research into double breaks in stem cells and their effect on tumor formation.

This article has been republished frommaterialsprovided byMIPT. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Tsvetkova, A., Ozerov, I. V., Pustovalova, M., Grekhova, A., Eremin, P., Vorobyeva, N., . . . Osipov, A. N. (2017). H2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation. Oncotarget. doi:10.18632/oncotarget.19203

Read this article:
Upon Prolonged Irradiation, Human Stem Cells' Defenses Are ... - Technology Networks

Agents acting on behalf of the Food and Drug Administration have seized what they said are unproven, and "potentially dangerous" stem cell treatments at two California clinics.

The seizures took place at the California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, California, where U.S. Marshals said they confiscated five vials of Vaccinia Virus Vaccine (Live) a vaccine the FDA said belonged to StemImmune Inc. of San Diego. The vaccine has been given to people at high risk for smallpox, such as some members of the U.S. military, but in this case was reportedly being used to treat cancer.

The FDA says Vaccinia Virus Vaccine (Live) is not commercially available, and therefore it is concerned about its origin. The FDA said an active investigation is underway to determine how the company obtained the vaccine.

"StemImmune, a biopharmaceutical company engaged in cutting edge R&D of adult human stem-cell based therapies for the treatment of cancer, is fully cooperating with the FDA about the development of its stem cell-based investigational cancer therapy," the company said in a statement to ConsumerAffairs. "We look forward to continuing our dialogue with the FDA as we seek to bring this important cancer therapy to cancer patients."

"Speaking as a cancer survivor, I know all too well the fear and anxiety the diagnosis of cancer can have on a patient and their loved ones and how tempting it can be to believe the audacious but ultimately hollow claims made by these kinds of unscrupulous clinics or others selling so-called cures," said FDA Commissioner Dr. Scott Gottlieb.

Gottlieb said the agency is concerned that potential cures are being offered vulnerable patients without offering any proof they actually work.

"I especially won't allow cases such as this one to go unchallenged, where we have good medical reasons to believe these purported treatments can actually harm patients and make their conditions worse," he said.

According to the FDA, clinics were using the product by injecting it directly into patents' tumors. The danger, the agency says, is when unvaccinated people are in close contact with someone who has been vaccinated, and are accidentally infected.

For its part, Steminnune notes on its website it provides "a potent new class of immunotherapies to wage a targeted, stealth attack on cancer."

See the rest here:
US Marshals seize 'unapproved' cancer treatment - ConsumerAffairs

Credit: MIPT

Researchers from several Russian institutes, including MIPT, have found out how prolonged exposure to ionizing radiation affects human stem cells. They discovered that it causes a cell cycle delay, which leads to faster repairs of radiation-induced DNA double-strand breaks, with fewer errors. It is unclear what the health implications are, in particular, how this affects the risk of developing cancer. The paper was published in Oncotarget.

Ionizing radiation is capable of turning neutral atoms and molecules into charged ions. The human body is inevitably exposed to natural background radiation, with an average person receiving about 3 milligrays of radiation annually. Moreover, one X-ray exam amounts to anywhere from 0.001 to 10 milligrays of additional exposure, depending on the exact procedure. That said, overexposure is dangerousa dose of more than 1,000 milligrays received within a brief period of time causes acute radiation sickness.

To ensure radiation security, it is vital to assess the risks posed by ionizing radiation. Studies of people exposed to radiation have only conclusively established the increased risk of cancer as a result of receiving a high dose of radiation. This led regulating authorities to accept a linear model under which low doses of radiation also increase the risk of cancer. However, experiments show that low-dose radiation exposure either had no adverse biological effect or was even beneficial, as evidenced by prolonged lifespans and less frequent cancer occurrence.

Apart from that, the importance of the so-called dose rate should not be overlooked. Exposure to equal doses of radiation over shorter or longer time intervals has a different effect, with "slow" irradiation causing less harm. The extent to which dose rate affects the biological outcomes is a cause of much debate. In a real-life setting, people are more likely to face prolonged exposure to low-dose radiation, so it is crucial that we understand its effects.

DNA double-strand breaks

One of the negative effects of radiation is the formation of the so-called DNA double-strand breaks, in which both strands of the double helix are severed. Fortunately, the cell is capable of repairing damaged DNA. If one of the two strands is damaged, the other can be used to repair it. However, in the case of a double-strand break, more error-prone mechanisms have to be employed. Left unrepaired or misrepaired, such lesions can give rise to oncological diseases. This explains why research into the effects of radiation on living cells tends to focus on double-strand breaks. Not long ago, it was found that stem cellsfunctionally undifferentiated cellsplay a major part in the formation of tumors by accumulating mutations and passing them on to the specialized cells that are their descendants. However, stem cell response to prolonged irradiation remains poorly understood.

The scientists conducted several experiments using stem cells derived from gingivae, or the gums. They treated the cells with identical radiation doses administered over long and short time spans. The formation of double-strand breaks was monitored using stained H2AX and 53BP1 proteins as markers. With brief but intense radiation exposure, the incidence of both markers was found to increase linearly with the dose. But in the case of prolonged irradiation, the response was linear only up to a certain point, followed by a plateau at 1,000 milligrays. In other words, after reaching a certain number, the lesion count does not continue to rise. A balance of sorts is achieved between break formation and repair.

DNA repair

The cell comes equipped with repair systems capable of mending DNA double-strand breaks. However, following intense irradiation, the cell has to resort to a mechanism known as end joininga quick but faulty procedurein eight out of 10 double-strand breaks. This often leads to chromosomal aberrations. Such misrepairs of DNA breaks can potentially result in cell death, oncogene activation, and anti-oncogene suppression. But there is an alternative mechanism of DNA repair, called homologous recombination. It uses a similar or identical DNA molecule as a template and produces far fewer errors, but it is only available during certain phases in the cell cycle. The researchers monitored homologous recombination using Rad51, another protein marker. During a two-hour long exposure, the amount of Rad51 remained roughly constant, followed by a linear growth afterward. The team hypothesized that prolonged irradiation might activate homologous recombination.

Cell division

Stem cells can be divided into two groups, called proliferating and quiescent, in which the former undergo division, the latter have ceased reproducing, and there is a balance between the two types of cells. The researchers counted the DNA double-strand breaks in proliferating and quiescent cells separately. This is made possible by a certain protein that is only found in cells undergoing division. It turned out that in both types of cells, the number of DNA breaks grew, eventually reaching a constant value.

The researchers also observed that exposure to radiation did not change the roughly four to one ratio between proliferating and quiescent cells. However, a more detailed investigation revealed that four hours of "slow" irradiation results in a considerably increased number of cells in the S and G2 phases of the cyclethat is, DNA synthesis and final preparation for division, respectively. It is during these phases that a copy of the cell's DNA is available for the sake of division, but also to be used as a template in homologous recombination. This fact is a likely explanation for the detection of increased amounts of the Rad51 marker. To put it another way, irradiation causes a delay in the cell cycleas a result, at any given time, there are more cells in those phases that enable homologous recombination. This means it is possible to repair DNA double-strand breaks correctly.

"We have shown that prolonged irradiation of mesenchymal stem cells leads to cell cycle redistribution. This might influence the biological response to radiation," says Sergey Leonov, the director of the Phystech School of Biological and Medical Physics. "Our findings could become the basis of further research into double breaks in stem cells and their effect on tumor formation."

Explore further: How breaks in DNA are repaired

More information: Anastasia Tsvetkova et al, H2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation, Oncotarget (2017). DOI: 10.18632/oncotarget.19203

Read the rest here:
Human stem cell defenses activated by irradiation, study finds - Phys.Org

Bacterial infection activates hematopoietic stem cells in the bone marrow and significantly reduces the ability to produce blood through induced proliferation. Credit: Professor Hitoshi Takizawa

It has been thought that only immune cells would act as the line of defense during bacterial infection. However, recent research has revealed that hematopoietic stem cells, cells that create all other blood cells throughout an individual's lifetime, are also able to respond to the infection. A collaboration between researchers from Japan and Switzerland found that bacterial infection activates hematopoietic stem cells in the bone marrow and significantly reduces their ability to produce blood by forcibly inducing proliferation. These findings indicate that bacterial infections might trigger dysregulation of blood formation, such as that found in anemia or leukemia. This information is important to consider in the development of prevention methods for blood diseases.

Background: Bacterial Infection and the Associated Immune Reaction

When a person becomes infected with a virus or bacteria, immune cells in the blood or lymph react to the infection. Some of these immune cells use "sensors" on their surfaces, called Toll-like receptors (TLR), to distinguish invading pathogens from molecules that are expressed by the host. By doing so, they can attack and ultimately destroy pathogens thereby protecting the body without attacking host cells.

Bone marrow contains hematopoietic stem cells which create blood cells, such as lymphocytes and erythrocytes, throughout life. When infection occurs, a large number of immune cells are activated and consumed. It therefore becomes necessary to replenish these immune cells by increasing blood production in bone marrow. Recent studies have revealed that immune cells are not the only cells that detect the danger signals associated with infection. Hematopoietic stem cells also identify these signals and use them to adjust blood production. However, little was known about how hematopoietic stem cells respond to bacterial infection or how it affected their function.

Proof: Hematopoietic Stem Cell Response to Bacterial Infection

Researchers from Kumamoto University and the University of Zurich analyzed the role of TLRs in hematopoietic stem cells upon bacterial infection, given that both immune cells and hematopoietic stem cells have TLRs. Lipopolysaccharide (LPS), one of the key molecules found in the outer membrane of gram negative bacteria and known to cause sepsis, was given to laboratory animals to generate a bacterial infection model. Furthermore, researchers analyzed the detailed role of TLRs in hematopoietic stem cell regulation by combining genetically modified animals that do not have TLR and related molecules, or agents that inhibit these molecules.

The results showed that LPSs spread throughout the body with some eventually reaching the bone marrow. This stimulated the TLR of the hematopoietic stem cells and induced them to proliferate. They also discovered that while the stimulus promoted proliferation, it also induced stress on the stem cells at the same time. In other words, although hematopoietic stem cells proliferate temporarily upon TLR stimulation, their ability to successfully self-replicate decreases, resulting in diminished blood production. Similar results were obtained after infection with E. coli bacteria.

Future Work

This study reveals that hematopoietic stem cells, while not in charge of immune reactions, are able to respond to bacterial infections resulting in a reduced ability to produce blood. This suggests that cell division of hematopoietic stem cells forced by bacterial infection induces stress and may further cause dysregulated hematopoiesis like that which occurs in anemia or leukemia. "Fortunately we were able to confirm that this molecular reaction can be inhibited by drugs," said one of the study leaders, Professor Hitoshi Takizawa of Kumamoto University's IRCMS. "The medication maintains the production of blood and immune cells without weakening the immune reaction against pathogenic bacteria. It might be possible to simultaneously prevent blood diseases and many bacterial infections in the future."

This finding was posted online in Cell Stem Cell on 21 July 2017, and an illustration from the research content was chosen as the cover of the issue.

Explore further: Innate reaction of hematopoietic stem cells to severe infections

More information: Hitoshi Takizawa et al, Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness, Cell Stem Cell (2017). DOI: 10.1016/j.stem.2017.06.013

Journal reference: Cell Stem Cell

Provided by: Kumamoto University

Go here to read the rest:
Bacterial infection stresses hematopoietic stem cells - Medical Xpress

Editors note: This is the first installment in a three-part series exploring the debate over Lyme disease diagnosis and treatment, and how it has affected Rhode Island and those with the disease locally.

North Kingstown resident Joe Russo used to be a healthy, active man.

Along with providing for himself through full-time employment, Russo was an avid hunter, always searching for game during his downtime. He also rode bicycles up and down his neighborhood.

Then, more than a decade ago, things began to change. He continued his normal daily routine but had weird symptoms that would come and go, or just didnt feel right. He would seek medical treatment to find out what was wrong, but the doctors only said he was either anxious, depressed or had allergies.

So, you try all the things they tell you and you keep trucking, he said.

The symptoms would subside, he added, but months later he would experience these other flares and weird stuff, like vertigo, dizzy spells or sweats.

As the years passed, Russo did not get better. He sought testing for everything under the sun cancer and heart issues, among others to get an answer for why his condition was deteriorating. However, the doctors at the time failed to test for another possibility Lyme disease.

Russo ultimately saw another doctor and received a confirmed diagnosis of the tick-borne disease. Relieved at finally having an answer, he went back to his primary care physician to plan a course of action.

But the response he got was unexpected.

When I went back to [my physician] with the positive lab [results], telling her, OK, we have an answer, she dismissed me, he said. Our relationship was very good. She was always caring. She tested me for everything, but once she found out I had Lyme, she wanted nothing to do with me.

Russo said he inquired in writing to seek an explanation for the dismissal, but received no response.

She left me with no reason, he said.

He added, That was humbling and it actually hurt. A doctor can dismiss you with this and theres nothing you can do about it.

***

Lyme disease is an extremely complex illness with no known cure. It can produce an array of symptoms, such as fatigue, joint pain, arthritis, muscle aches, palsy, tingling and twitching muscles and other neurological symptoms. The most common symptom is a rash, often in a bulls-eye pattern.

Dr. Jim Gloor, a North Kingstown-based physician who has specialized in Lyme disease treatment for more than three decades, said Lyme-causing bacteria is one of the most complex eukaryotic cells. Typically, he said, a persons immune system is supposed to sort out what is foreign and what is not inside a persons body. But Lyme-causing bacteria is so effective in evading the immune system that it overheats the immune engine, causing a sufferers health to go haywire.

Its like when you race an old Chevy down the highway at 100 mph over a bumpy road, somethings going to break, he said. The immune system goes haywire and we have fallout from it that ends up being other conditions that are autoimmune, which is a nice way of saying, We dont know exactly why the immune system went sour.

Gloor said the medical community has yet to fully understand the immune system and autoimmunity. Because of that, he said, a lot more research needs to be done, particularly because Lyme disease is so sophisticated.

It confuses and confounds the immune system, and it confounds the body in general, he said.

The complexity has caused confusion over how Lyme disease is diagnosed, and led to intense debate locally and nationally about treatments and whether the disease can be designated as chronic.

Dr. Utpala Bandy, a state epidemiologist and medical director for the Rhode Island Department of Healths Division of Preparedness, Infectious Disease and Emergency Medical Services, said July 26 while the state does not develop, produce, approve or endorse any guidelines on treating Lyme disease, two main sets of guidelines are in place nationally for physicians to follow.

One comes from the Infectious Diseases Society of America, or IDSA, in conjunction with the Centers for Disease Control and Prevention, and the other from the International Lyme and Associated Diseases Society, or ILADS.

The organizations have conflicting views of Lyme disease treatment and diagnoses of long-term Lyme disease.

According to the state Department of Healths Jan. 31, 2016, report on Lyme disease, the IDSA/CDC guidelines indicate patients should take the antibiotic doxycycline for several Lyme disease symptoms, including the bulls-eye rash, palsy, cardiac disease, arthritis without neurological involvement and recurrent arthritis after a single course of antibiotics.

IDSA, according to its 2006 report Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines, also maintains there is no convincing evidence for the existence of a chronic borrelia burgdorferi infection the bacteria that causes Lyme disease in patients who have received the recommended treatments. The report states antibiotic therapy is not recommended for patients with chronic Lyme disease lasting longer than six months.

In June, CDC published in its Morbidity and Mortality Weekly Report an article that also warns of serious risks for Lyme patients receiving antibiotic and intravenous treatment, even resulting in serious harm, including death.

The introduction to the article, titled Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease United States, reads: The term chronic Lyme disease is used by some health care providers as a diagnosis for various constitutional, musculoskeletal, and neuropsychiatric symptoms. Patients with a diagnosis of chronic Lyme disease have been provided a wide range of medications as treatment, including long courses of intravenous (IV) antibiotics. Studies have not shown that such treatments lead to substantial long-term improvement for patients, and they can be harmful. This report describes cases of septic shock, osteomyelitis, Clostridium difficile colitis, and paraspinal abscess resulting from treatments for chronic Lyme disease. Patients, clinicians, and public health practitioners should be aware that treatments for chronic Lyme disease can carry serious risks.

Other treatments, including IV infusions of hydrogen peroxide, immunoglobulin therapy, hyperbaric oxygen therapy, electromagnetic frequency treatments, garlic supplements, colloidal silver, and stem cell transplants, are also presented as being risky and not shown to produce favorable results.

The article further states, At least five randomized, placebo-controlled studies have shown that prolonged courses of IV antibiotics in particular do not substantially improve long-term outcome for patients with a diagnosis of chronic Lyme disease and can result in serious harm, including death. Five specific cases are cited to support the articles assertions.

In contrast, ILADS states on its website that it is impossible to state a meaningful success rate for the prevention of Lyme disease by a single 200 mg dose of doxycycline, and advises clinicians should not use a single doxycycline dose for treatment due to very-low quality evidence.

An optimal treatment regimen has not yet been determined, ILADS states, adding that it is too early to standardize restrictive protocols. ILADS recommends patient goals and values regarding treatment options be identified and strongly considered during a shared decision-making process.

ILADS President Dr. Samuel Shor pushed back against the CDCs June 16 report in a June 23 post on the National Center for Biotechnology Informations website. He notes one National Institutes of Health-supported study, in which 37 patients suspected of having active neuroborrelliosis a central nervous system disorder caused by Lyme disease received 10 weeks of IV Ceftriaxone, or two grams a day of the antibiotic. Pain and physical functioning improved at 12 [weeks] and was sustained at 24 weeks, Shor states.

Shor also points to another NIH-supported study in which 55 patients who felt they had an active infection of the main Lyme disease bacteria and experienced severe fatigue for longer than six months received 28 days of IV Ceftriaxone. According to Shor, a significant improvement in fatigue was sustained at 6 months.

While there are conflicting viewpoints regarding how Lyme disease should be approached and treated, one local advocate believes the state sides with the IDSA/CDC guidelines which, he believes, are outdated.

***

Lane Poor, a North Kingstown resident, was first diagnosed with Lyme disease in 1983 and still feels the effects of the disease. He has traveled around the state for years making residents aware of the disease and its harmful effects especially if it goes undetected.

In an interview in June, he said he believes the state cant accept the fact that Lyme disease is a major problem in Rhode Island, mainly because it is complicated, messy and there is no silver bullet in terms of treatment. He said the disease can result in multiple infections following the initial infection from a tick bite, and doctors are not used to it being multiple infections.

Theyre used to it as, Its one disease and you have that one thing that will kill the one disease. That doesnt happen with Lyme, he said. Lyme disease, you can get other infections. It is so hard for doctors to identify whats going on because youve got three, four different infections. Its a compound disease, and were not used to treating compound diseases.

Poor also believes there are many more Lyme disease cases in Rhode Island than the Department of Health has reported. In 2014, Rhode Island, at 86 cases per 100,000 people, had the fourth-highest Lyme disease rate in the U.S. Bandy said the department processes approximately 3,000 test reports for surveillance every summer, and of that amount, approximately 900 new Lyme disease cases are determined annually.

Poor, though, thinks Rhode Islands rate may be 10 times higher than the official figure.

Massachusetts has got an infection rate of about 800 people per 100,000, and RIDOH says we have 80, he said. Were neighbors with Massachusetts.

Both Poor and Gloor are critical of the CDCs recommended two-tier testing regimen. CDC suggests doctors first order a test known as an enzyme-linked immunosorbent assay, or ELISA, to screen for Lyme disease and then confirm it with a western blot, a procedure used to detect specific proteins.

However, according to the advocacy group LymeDisease.org, a 2002 study by Massachusetts Dr. Samuel Donta revealed 52 percent of patients with chronic Lyme disease are considered negative by the ELISA test, but the western blot shows a positive result. The College of American Pathologists, according to a 1997 study, found that ELISA tests do not have adequate sensitivity to be used for screening purposes.

Gloor said in about half of his cases, the tests are negative across the board.

LymeDisease.org states a quality test can help a doctor assess the diseases severity, estimate a patients prognosis, monitor the diseases progression, detect relapses or adjust therapies.

Unfortunately, a test with this capability does not exist for Lyme disease, according to LymeDisease.org.

Donta also said the tests are indirect and do not indicate whether or not the Lyme disease bacteria is still present. Until a proven test is developed, he said, clinical judgment and observations ... should be how one proceeds to treat such patients.

Bandy said physicians and patients can do whatever they want as long as it is a shared decision-making process.

But Lyme disease specialists in Rhode Island and beyond have had their methods questioned by health officials.

***

Over more than five years, Gloor was called to appear before the Department of Healths Board of Medical Licensure and Discipline multiple times to answer allegations from several complainants regarding his regimens for treating long-term Lyme disease, mostly with antibiotics and intravenous medicines.

The complaints, according to a 2014 consent decree filed with the health department, which was obtained by The Independent, were received by the board in 2012 and 2013, and the panel questioned the reasonableness of the diagnosis and treatment plans.

While the board found no wrongdoing regarding Gloors regimens in 2014, the decree indicates he was penalized for failing to properly document diagnoses in the assessment and plan sections of certain medical charts and with respect to the legibility of patient records. He was ordered to pay a $1,935 administrative fee to the health department and was placed on a monitoring period for one year.

In December 2016, Gloor was again cited by the Board of Medical Licensure and Discipline for poor record keeping, according to a second consent decree filed with the health department, which also indicated Gloors handwriting was barely legible and his script was so large there is only room for the barest information.

Gloor agreed to a reprimand and paid an administrative fee of $500. He additionally agreed to complete eight hours of continuing education regarding record keeping, health department spokeswoman Annemarie Beardsworth said in an email July 24.

Poor was sharply critical of the health departments dealings with Gloor, and indicated other local physicians had been treated similarly. He said the consent decrees amount to health officials serving as judge, jury and executioner all in one thing.

Doctors are scared stiff theyre going to be brought before the board for treating Lyme disease, so they dont [treat it], he added. A lot of doctors have refused to have anything to do with it.

Gloor said the issues with the health department have taken a toll emotionally and mentally, and have had a significant negative impact on his practice. He was forced to move from his former office at Wickford Junction to a new space on Post Road.

This tied me up for years, he said. My practice went to hell.

nk@independentri.com

Go here to read the rest:
Behind the Lyme disease debate: 'No silver bullet' for confounding ailment - The Independent

MedicalResearch.com Interview with:Michael Sigal PhDClinical scientist of the Charit Universittsmedizin BerlinInvestigator at the Max Planck Institute for Infection Biology

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: We have previously found that H. pylori can colonize gastric glands and that in colonized glands the epithelial turnover was increased. We wanted tocharacterizethe mechanisms that control the gland turnover in thestomach.

We foundthat Axin2, a classic Wnt target gene, marks two different subpopulations of cells with stem cell properties, one of which is Lgr5-positive and theotherone Lgr5-negative. Bothpopulations are affected by Rspondin 3, that isproduced in myofibroblasts right beneath the stem cell compartment. Rspondin is crucial for stem cell signaling andknockout of Rspondin 3 in myofibroblastsresults in loss of Lgr5 and Axin2 expression. Once weincreased thebioavailability of Rspondin, that now could also interact with cells outside of the stem cellcompartment, we noticed that the number of Axin2positive stem cells dramatically increased. Of interest, only Lgr5-negative cells expanded in number and proliferate more, while the Lgr5-positive cells remained silenced.

Infection with Helicobacter pylori leads to an expansion of Axin2-positive cells which is driven by increased expression of Rspondin3. Expansion of the long lived stem cell pool could be an explanation for how H. pylori infectionincreases the risk for gastric cancer.

MedicalResearch.com: What should clinicians and patients take away from your report?

Response: It is interesting how different cell types of the tissue communicate with each other and we show an example, including the molecular details, how thiscommunication is organized and how itdynamically adapts to infection.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: I think it will be very important to address the question of how and why different subpopulations of stem cells can have differential responses to the same stimulus. What is the molecular basis for this. And also, what are the consequences?

No financial conflicts of interest.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Michael Sigal, Catriona Y. Logan, Marta Kapalczynska, Hans-Joachim Mollenkopf, Hilmar Berger, Bertram Wiedenmann, Roeland Nusse, Manuel R. Amieva, Thomas F. Meyer.Stromal R-spondin orchestrates gastric epithelial stem cells and gland homeostasis.Nature, 2017; DOI:10.1038/nature23642

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

Link:
H. pylori May Increase Risk of Stomach Cancer By Turning On Subset of Stem Cells - MedicalResearch.com (blog)

[ACCESSWIRE]

SUNRISE, FL / ACCESSWIRE / August 23, 2017 / Kristin Comella, Chief Science Officer at U.S. Stem Cell, Inc. (OTCQB: USRM), was named number 45 on the list of Top 50 Functional and Integrative Medical Doctors in the country by DrAxe.com, one of the most visited natural health websites in the world that covers nutrition, natural medicine, and trending health news. The list also features Dr. Mehmet Oz, MD; Dr. Mark Hyman, MD; Dr. Andrew Weil, MD and other doctors and scientists who are truly shaping the functional and integrative medicine fields.

Kristin is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapin's list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Learn more here.

"Kristin is lauded as an expert on regenerative medicine, the study of using the body's own regenerative capabilities to treat diseases and injuries," according to the Dr.Axe.com article. "She led the team that was the first to gain FDA approval for a clinical trial that used a combination of cell and gene therapy for the heart and pioneered stem cell therapy of adipose tissue, as well as cord blood, bone marrow and muscle, helping people recover from disease and lead normal lives."

"It's an honor to be featured on Dr. Axe's prestigious list of influencers in the integrative medicine field," Comella said in a statement. "There are some amazing scientists and doctors on this list." DrAxe.com is one of the top websites in the natural medicine industry with 14 million unique visitors each month.

Comella is the Chief Science Officer at U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients. Watch this video as Kristin talks more about stem cell therapy and how it works.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Media Contact:

U.S. Stem Cell, Inc.13794 NW 4th Street, Suite 212 Sunrise, Fl 33325Phone: 954.835.1500Email: usstemcell@us-stemcell.com

SOURCE: U.S. Stem Cell, Inc.

More:
Kristin Comella, US Stem Cell's CSO, Named to the List of Top 50 Functional and Integrative Medical Doctors By DrAxe ... - Baystreet.ca

The National Institute of Healthcare and Excellence (NICE) is set to reject Pfizers orphan drug for leukaemia Besponsa (inotuzumab ozogamicin).

Pfizer issued a robust defence of its product, saying the UK cost-effectiveness watchdogs final appraisal determination had inappropriately assessed the drugs value.

The firm added that assumptions made during the process were inconsistent with previous appraisals of other medicines in the disease area.

David Montogomery, oncology medical director at Pfizer UK, said: [This] frustrating decision for inotuzumab ozogamicin is another example of how NICE is not appropriately assessing the value of modern cancer medicines, leaving patients without access to new treatments that could transform their lives.

We will continue to work with NICE in the hope that this decision can be overturned.

The cost-effectiveness watchdog was assessing Besponsas use to treat adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL).

NICE compared Besponsa to the current usual treatment of fludarabine, cytarabine and granulocyte (FLAG) chemotherapy with idarubicin, but found clinical trial evidence did not show an overall survival benefit.

For its part Pfizer pointed to the INO-VATE trial, which showed Besponsa more than doubled complete remission rates (81% versus 29%).

When compared to chemotherapy the drug also showed that nearly four times as many patients were able to receive stem cell transplant (43% versus 11%).

NICE accepted more Besponsa patients went on to have a stem cell transplant, but said its cost-effectiveness estimates were too high, despite a patient access scheme being in place.

Besponsa has orphan status in Europe, where regulators approved it in June, and the treatment has just been licensed in the US, where it has breakthrough status.

NICEs negative final appraisal determination is now out for consultation and Pfizer plans to appeal the ruling, which is currently due to be finalised by 27 September.

Originally posted here:
NICE set to reject Pfizer's leukaemia drug Besponsa - PMLiVE

When Raymond Funnell, 52, was diagnosed with leukaemia, he had no idea he would survive to climb five of the worlds highest mountains.

Funnell was just over 40 and working as a consulting engineer for a Joburg mining company when he was diagnosed with acute myeloid leukemia (AML) in 2006. This was is after he noticed a bruise on his arm that wouldnt heal.

I had always been fit and healthy so it came as a big shock that cancer was spreading rapidly in my bone marrow.

I was on put on chemotherapy and within no time I was in an isolation ward in hospital as I had no immune system.

At that stage, I had no idea just how hard or how long the treatment was going to be and that it would totally change my outlook on life. My wife and young family were devastated to hear what was about to happen to our normal life.

While he was recovering in hospital, Funnell would shuffle out of his isolation room in the still of the night and slow-walk along the corridors.

He says when the nurses moaned at him to take it easy, the idea of climbing Kilimanjaro was inspired.

For motivation, my wife put up a picture of Kilimanjaro on my room wall. By the middle of 2010, I was ready to make this dream a reality. It was such a spiritual experience, reaching the top of Africas highest point.

Since 2010 he has climbed Mount(Mt) Kilimanjaro, Mt Aconcagua in South America and Mt Vinson in Antarctica.

He attempted to climb Mt Elbrus in Russia in 2012 but 100m from the summit he was held back by poor weather conditions.

Despite the setbacks experienced along the way, including the recurrence of cancer two years after his initial diagnosis, Funnell, who is currently in remission, refuses to give up on life. And this month he has gone back to Russia to reattempt his climb of Mt Elbrus.

This is the highest peak in Europe at an altitude of 5642m, and Funnell hopes to climb it in five days to raise awareness about cancer and stem cell donation.

Not only do I want to inspire other cancer patients, but I also want raise awareness about the need for people to register as stem cell donors. If all goes well, we hope to be holding the Sunflower Fund banner high above our heads on August 17.

Funnell says he wants other people to also benefit from the life-saving stem cell treatment, which saved his life 10 years ago.

I was fortunate to have a perfect match with my brother and we made plans to have the stem cell transplant at the beginning of 2007. The stem cell infusion was uneventful and then it was a waiting game until the new bone marrow was able to produce new blood.

It changed my blood type from A-negative to O-negative. Due to all the anti-rejection drugs, I had a weak immune system and lost a huge amount of weight. I was convinced I was cured, but in March 2008 a routine blood test showed I had relapsed. It was such a feeling of hopelessness.The oncologist was stunned that I had relapsed after the stem cell transplant, he recalled.

After the relapse the only remaining option was high dose chemotherapy, which is about 20 times the concentration of the induction treatment.

The risks were high and this would be a real fight for survival. He spent most of the year between chemo treatments, blood transfusions and isolation wards.

The treatment was very severe and left my body weak and anaemic. I had over 50 blood transfusions and therefore I am truly thankful for all the donors who kept me alive.

Funnells experience opened up a new world and took away the feeling of limitations.

Never give up on your dreams, he says. It may be impossible to get to the top of a mountain in one single step, but by taking many small steps you can climb any summit in your life. Just keep going, step by step, and a day at a time

For more information on becoming a blood stem cell donor contact The Sunflower Fund on the toll-free number 0800 12 10 82

View post:
Climbing for cancer and donor awareness - Independent Online

Shares ofStemcell United Ltd (SCU.AX) are on watch as the Tenkan Line has moved belowthe Kijun line, indicating negative momentum for the equity. Stemcell United Ltd moved0.00 in the most recent session and touched0.07 on a recent tick.

The Tenkan Line or Tenkan Sen (Sen means line in Japanese) is known as the conversion line or turning line is similar to a 9SMA but actually is quite different. Remember a SMA (simple moving average) will smooth out all the data and make it equal but the Tenkan Line will take the highest high and lowest low over the last 9 periods. The explanation for this is Hosada felt price action and its extremes were more important than smoothing any data because price action represented where buyers/sellers entered and directed the market, thus being more important than averaging or smoothing the data out. As you can see by the chart below, the Tenkan Line is quite different than a 9SMA. Because the TL (Tenkan Line) uses price instead of an averaging or the closing prices, it mirrors price better and is more representative of it. You can see this when the TL flattens in small portions to move with price and its moments of ranging.

Akin to all moving averages, the angle of the Tenkan line is very important as the sharper the angle, the stronger the trend while the flatter the Tenkan, the flatter or lesser the momentum of the move is. However, it is important to not use the Tenkan line as a gauge of the trend but more so the momentum of the move. However, it can act as the first line of defense in a trend and a breaking of it in the opposite direction of the move can often be a sign of the defenses weakening.

Turning to addtiional indicators, Stemcell United Ltd (SCU.AX) currently has a 14-day Commodity Channel Index (CCI) of -87.92. Dedicated investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Investors may be trying to define which trends will prevail in the second half of the year. As the markets continue to chug along, investors may be trying to maximize gains and become better positioned for success. Technical analysts may be studying different historical price and volume data in order to help uncover where the momentum is headed. Coming up with a solid strategy may take some time, but it might be well worth it in the long run. As we move deeper into the year, investors will be closely tracking the next few earnings periods. They may be trying to project which companies will post positive surprises.

We can also do some further technical analysis on the stock. At the time of writing, the 14-day ADX for Stemcell United Ltd (SCU.AX) is 32.59. Many technical chart analysts believe that an ADX value over 25 would suggest a strong trend. A reading under 20 would indicate no trend, and a reading from 20-25 would suggest that there is no clear trend signal. The ADX is typically plotted along with two other directional movement indicator lines, the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI). Some analysts believe that the ADX is one of the best trend strength indicators available.

Interested investors may be watching the Williams Percent Range or Williams %R. Williams %R is a popular technical indicator created by Larry Williams to help identify overbought and oversold situations. Investors will commonly use Williams %R in conjunction with other trend indicators to help spot possible stock turning points. Stemcell United Ltd (SCU.AX)s Williams Percent Range or 14 day Williams %R currently sits at -100.00. In general, if the indicator goes above -20, the stock may be considered overbought. Alternately, if the indicator goes below -80, this may point to the stock being oversold.

Tracking other technical indicators, the 14-day RSI is presently standing at 36.37, the 7-day sits at 35.27, and the 3-day is resting at 38.98 for Stemcell United Ltd (SCU.AX). The Relative Strength Index (RSI) is an often employed momentum oscillator that is used to measure the speed and change of stock price movements. When charted, the RSI can serve as a visual means to monitor historical and current strength or weakness in a certain market. This measurement is based on closing prices over a specific period of time. As a momentum oscillator, the RSI operates in a set range. This range falls on a scale between 0 and 100. If the RSI is closer to 100, this may indicate a period of stronger momentum. On the flip side, an RSI near 0 may signal weaker momentum. The RSI was originally created by J. Welles Wilder which was introduced in his 1978 book New Concepts in Technical Trading Systems.

For further review, we can take a look at another popular technical indicator. In terms of moving averages, the 200-day is currently at 0.08, the 50-day is 0.09, and the 7-day is resting at 0.07. Moving averages are a popular trading tool among investors. Moving averages can be used to help filter out the day to day noise created by other factors. MAs may be used to identify uptrends or downtrends, and they can be a prominent indicator for detecting a shift in momentum for a particular stock. Many traders will use moving averages for different periods of time in conjunction with other indicators to help gauge future stock price action.

Original post:
Bearish Signals Shown in Stemcell United Ltd (SCU.AX) Charts ... - Evergreen Caller

For patients with severe and end-stage heart failure there are few treatment options left apart from transplants and stem-cell therapy. But a new Israeli study finds that stem-cell therapy may harm heart-disease patients.

The research, led by Prof. Jonathan Leor of Tel Aviv Universitys Sackler Faculty of Medicineand Sheba Medical Center and conducted by TAUs Dr. Nili Naftali-Shani, explores the current practice of using cells from the host patient to repair tissue and contends that this can prove toxic for patients.

We found that, contrary to popular belief, tissue stem cells derived from sick hearts do not contribute to heart healing after injury, said Leor. Furthermore, we found that these cells are affected by the inflammatory environment and develop inflammatory properties. The affected stem cells may even exacerbate damage to the already diseased heart muscle.

Tissue or adult stem cells blank cells that can act as a repair kit for the body by replacing damaged tissue encourage the regeneration of blood vessel cells and new heart muscle tissue. Faced with a worse survival rate than many cancers, many heart-failure patients have turned to stem-cell therapy as a last resort.

But our findings suggest that stem cells, like any drug, can have adverse effects, said Leor. We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient.

The researchers, who published their study in the journal Circulation, also discovered the molecular pathway involved in the negative interaction between stem cells and the immune system as they isolated stem cells in mouse models of heart disease. Afterward, they focused on cardiac stem cells in patients with heart disease.

The results could help improve the use of autologous stem cells those drawn from the patients themselves in cardiac therapy, Leor said.

We showed that the deletion of the gene responsible for this pathway can restore the original therapeutic function of the cells, said Leor. Our findings determine the potential negative effects of inflammation on stem-cell function as theyre currently used. The use of autologous stem cells from patients with heart disease should be modified. Only stem cells from healthy donors or genetically engineered cells should be used in treating cardiac conditions.

The researchers are currently testing a gene editing technique (CRISPER) to inhibit the gene responsible for the negative inflammatory properties of the cardiac stem cells of heart disease patients. We hope our engineered stem cells will be resistant to the negative effects of the immune system, said Leor.

Read the rest here:
Stem-cell treatment may harm heart disease patients - ISRAEL21c

August 10, 2017 - By Louis Casey

Investors sentiment decreased to 0.3 in Q4 2016. Its down 0.37, from 0.67 in 2016Q3. It turned negative, as 16 investors sold Neuralstem, Inc. shares while 11 reduced holdings. 2 funds opened positions while 6 raised stakes. 6.88 million shares or 44.05% less from 12.30 million shares in 2016Q3 were reported.Fifth Third Bank & Trust accumulated 120,000 shares. Moreover, Northern has 0% invested in Neuralstem, Inc. (NASDAQ:CUR). Geode Capital Mgmt Limited Liability Company, Massachusetts-based fund reported 1.03 million shares. Blair William Il holds 0% or 418,942 shares. National Bank Of Mellon Corp owns 0% invested in Neuralstem, Inc. (NASDAQ:CUR) for 91,969 shares. California Public Employees Retirement invested in 155,700 shares. Wells Fargo And Mn stated it has 0% in Neuralstem, Inc. (NASDAQ:CUR). Vanguard Group Incorporated Inc invested in 3.09 million shares or 0% of the stock. The California-based Blackrock Institutional Na has invested 0% in Neuralstem, Inc. (NASDAQ:CUR). National Asset Mgmt Incorporated invested in 0.01% or 167,500 shares. Natl Bank Of America Corp De, North Carolina-based fund reported 8,400 shares. Blackrock Advisors reported 17,361 shares. First Heartland Consultants accumulated 10,000 shares. Kcg Holding reported 0% in Neuralstem, Inc. (NASDAQ:CUR). Gru One Trading L P accumulated 4,349 shares.

Since February 24, 2017, it had 3 buys, and 0 insider sales for $70,004 activity. LLOYD JONES JONATHAN BRIAN had bought 5,455 shares worth $30,003. 7,500 shares were bought by Daly Richard J, worth $30,000.

The stock of Neuralstem Incorporated (NASDAQ:CUR) registered an increase of 0.98% in short interest. CURs total short interest was 942,000 shares in August as published by FINRA. Its up 0.98% from 932,900 shares, reported previously. With 90,000 shares average volume, it will take short sellers 11 days to cover their CURs short positions. The short interest to Neuralstem Incorporateds float is 11.11%.

It closed at $1.08 lastly. It is down 3.35% since August 10, 2016 and is uptrending. It has underperformed by 13.35% the S&P500.

Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $13.09 million. The Firm is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. It currently has negative earnings. The Firm has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

More notable recent Neuralstem, Inc. (NASDAQ:CUR) news were published by: Globenewswire.com which released: Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical on August 08, 2017, also Seekingalpha.com with their article: Neuralstem Is Doomed published on August 03, 2017, Globenewswire.com published: Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants on July 27, 2017. More interesting news about Neuralstem, Inc. (NASDAQ:CUR) were released by: Globenewswire.com and their article: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into published on August 02, 2017 as well as Benzinga.coms news article titled: Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View original post here:
What Will Happen to Neuralstem Incorporated (NASDAQ:CUR) Next? The Stock Has Increase in Shorts - BZ Weekly

It began over dinner on the Fourth of July.

Terri and David Bayne were sitting around a patio table on the deck of their old friends new townhouse.

Terri and David had a deck of their own a small one, hail-damaged and in need of paint at their house in northeast Lincoln.

They had a patio table, too, and a pair of chairs, one of them so rickety they had to turn it just so or it would tip over when you sat down.

Now their friends announced they were selling their old patio set tucked away in their garage and did they know anyone who might want to buy it?

As a matter of fact, Terri and David said, they did.

The friends wouldnt take the Baynes money and insisted on delivering the glass-topped table and six comfy chairs themselves.

But when they put it on the Baynes' deck, it looked like a king-sized bed in a bathroom.

It barely fit, Terri said Tuesday, driving back to work after a lunch date with David, hosted by his former colleagues at Home Real Estate.

David has been an agent for 38 years, the last five at Sellstate Performance Realty. For 34 of those years, he sold houses by day and worked nights at Goodyear.

Thats where he met Terri Murray. David had three kids of his own Mike and Ben and Carney and he and Terri had a son and named him Joe. Now they have five grandchildren.

People call David Big Teddy Bear.

Because hes such a wonderful man, Terri says. And hes an emotional type of guy. Hes not afraid to shed a tear.

Nearly seven years ago, David, 65, was diagnosed with two types of blood cancer. Last month, he updated his condition via Facebook.

The doctors have decided that we are out of options and will no longer be giving me any treatments, he wrote.

I knew that this day was coming but that day is not supposed to be here for many more tomorrows

He thanked everyone for their love and support and prayers.

And everyone started to type: What can we do to help?

The hot workers took a break in the shade Tuesday afternoon David and Terris nephew, a son-in-law born in South Africa, two brothers-in-law and Terris sister from down the street, sitting on those comfy patio chairs in the grass.

The old deck was gone. A pile of broken cement, a stack of splintering wood once painted red.

Ryan Mueller, the nephew, had built a deck at his house this spring, and he had a plan and a building permit.

They hoped to be done by Saturday, he said.

As they rested, the crew talked about David.

Son-in-law Sam Funnah called him Dr. Phil.

Hes just one of those people that you want to help, said Davids brother-in-law Doug Smith. Rarely have I heard him say anything negative about anyone.

By Wednesday, the holes for the footings were dug, 3 feet deep and round as silver dollars. Bags of cement were poured into a mixer, transforming the powder into wet concrete for the footings.

New faces filled the backyard.

And more arrived Thursday nieces and nephews; David and Terris son Joe; another son, Mike, home from Amman, Jordan.

The crew hauled heavy bags and hammered nails. Someone ran to the hardware store. Great-aunts watched a toddler named Henry.

David was inside resting.

Its hard for him to be sitting in the living room while theyre out back working, Terri said.

Hes always been the giver, so its hard for him to be the receiver.

The Murray girls are all married. Terri is the oldest, then Lorri (Warboys), then Lynn (Smith), then Danni (Brennan).

Danni and her husband, Troy, have been living in Dubai for the past six months for his job at Pfizer, but theyre back for three more weeks.

Danni is the brains behind the deck-building project. The idea came to her after Ryan, her son-in-law, posted photos of his own new deck on Facebook and Terri typed a reply: Do you hire out?

As soon as I read that, I said to some of the relatives, lets make this happen as soon as we can, Danni says.

Then she thought back to another post.

After David put out his message on Facebook there were 100 different comments. All these people saying, What can I do?

Its the universal refrain of those who feel helpless when someone is hurting: What can I do to help?

There it was. A need. And an offer.

Those people were willing to bless him, Danni said. And because everyone has their own gifts, I offered three ways to help. Financially, labor, food.

Then she remembers a fourth: Also prayer.

Tuesday night, a cousin brought pizza. We hadnt seen her for years.

Wednesday night, a former coworker from Goodyear fixed sloppy joes.

Thursday, a group of church friends organized a potluck.

The weather had turned cool, and David joined the party and they all sat around the patio table in the grass, admiring the new deck taking shape before their eyes.

David was once 6-foot-2, which is where the big in Big Teddy Bear comes from.

Hes shorter now by 4 inches. Its the cancer, causing his vertebrae to compress.

It basically pokes tiny holes in all my bones, he says.

The fan is blowing cool air in the living room where David rests in an overstuffed recliner, bottled water and a bag of peppermints nearby.

Earlier in the week, he and Terri walked four houses down the block to visit Terris sister Lorri and her husband, Larry, a 30-minute pilgrimage.

David is tired most of the time and always in pain, even though he doesnt complain. A cane rests by the recliner and a walker with wheels is folded nearby.

He just started using it.

Since he was diagnosed with multiple myeloma and amyloidosis, doctors have tried four kinds of chemotherapy and a stem cell transplant. Hes never gone into full remission. And even though he officially entered hospice last week, if a new study opened up or a new drug became available, hed try it, David says.

If it doesnt help him, maybe it will help someone else.

Hes still working. I had two nice closings this week.

He loves selling houses, helping buyers find new homes. And I love seeing new agents as they develop.

He shakes his head thinking about the new deck, that suburban barn-raising, all that work and love in his backyard.

I dont know, he says. Its too much.

Terri is the office manager at Sellstate, the real estate office where David works.

Last week, the owners brought in a personal life coach to help the agents clarify and work on their goals both professional and personal.

David went to listen to her talk, first in a group session and then one-on-one, when she explained the one-year individual program she offered.

He had cancer and was in hospice, David told her, so that probably wouldnt work for him.

Later, Terri asked him why hed gone, and he said that not very many people had signed up and he felt bad, because the company had gone to so much work to bring her in.

He said you can always learn something, so he listened, she said. Thats just David.

By Friday morning, the framing is finished.

By Friday evening, the crew has returned. Its work has been inspected and greenlighted by the city and its time for the decking.

Terri and David picked the color for the sturdy composite boards, an upgrade from their rotting wood with its peeling paint.

From the hardware store, Terri texted her sisters their choice rustic gray and told them she and David had the money to pay for it.

The Murray girls answered.

It will be covered, Lynn texted back. People asked. Also if we let them help it will be a blessing to them. People need to feel needed

So, no, David, you are not going to get money from your account, but nice try.

The checks are still coming. $25. $50. $300.

There is a sense of urgency about this deck, a feeling of summer slipping away, of David becoming too sick to enjoy it.

David likes the outdoor spaces at home. The old metal chairs out front, the deck off the kitchen, where hed slip outside to think and pray in the stillness on nights he couldnt sleep.

Theyll finish by the Saturday deadline, Ryan says, as this nights team of helpers a nephew named Austin; Davids daughter, Carney; Dannis husband, Troy; and a trio of Murray sisters picked up drills and started in.

This deck is bigger than the old one wider by 6 feet and deeper, too, with stairs down the side, so its a straight shot off the kitchen.

David sat in the yard, leaning on his walker, a bottle of peach tea in one hand.

Terri hugged him from behind.

Lorri and Danni grabbed a wheelbarrow and walked down the block, returning with a crock pot and covered dishes for tonights picnic.

David was quiet. A Big Teddy Bear in brown loafers, not afraid to die, but wishing he could be the one to say: What can I do to help?

Read the original here:
Cindy Lange-Kubick: Building a deck for David, the blessings of giving - Lincoln Journal Star

August 4, 2017 - By Marguerite Chambers

Neuralstem Inc (NASDAQ:CUR) institutional sentiment decreased to 0.3 in Q4 2016. Its down -0.37, from 0.67 in 2016Q3. The ratio worsened, as 8 institutional investors increased or opened new positions, while 27 sold and decreased their stakes in Neuralstem Inc. The institutional investors in our partners database now own: 6.88 million shares, down from 12.30 million shares in 2016Q3. Also, the number of institutional investors holding Neuralstem Inc in their top 10 positions decreased from 1 to 0 for a decrease of 1. Sold All: 16 Reduced: 11 Increased: 6 New Position: 2.

Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $18.31 million. The Firm is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. It currently has negative earnings. The Firm has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

About 412,558 shares traded or 2.10% up from the average. Neuralstem, Inc. (NASDAQ:CUR) has risen 3.35% since August 4, 2016 and is uptrending. It has underperformed by 13.35% the S&P500.

National Asset Management Inc. holds 0.01% of its portfolio in Neuralstem, Inc. for 167,500 shares. Bank Of America Corp De owns 8,400 shares or 0% of their US portfolio. Moreover, Bank Of New York Mellon Corp has 0% invested in the company for 91,969 shares. The Delaware-based Blackrock Advisors Llc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 24,841 shares.#img1#

Since January 1, 0001, it had 3 insider buys, and 0 selling transactions for $70,004 activity.

More important recent Neuralstem, Inc. (NASDAQ:CUR) news were published by: Globenewswire.com which released: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into on August 02, 2017, also Marketwatch.com published article titled: UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss, Seekingalpha.com published: Neuralstem Is Doomed on August 03, 2017. More interesting news about Neuralstem, Inc. (NASDAQ:CUR) was released by: Benzinga.com and their article: Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:
Institutional Investors Lead Shift in Neuralstem Inc (NASDAQ:CUR) Sentiment - BZ Weekly

Celgene Corp.'s (NASDAQ:CELG) second-quarter revenue and sales came in nearly 50% higher than they were two short years ago, yet the company doesn't appear to be anywhere near peaking. A flurry of R&D activity should provide it with a steady stream of label expansion and new drug opportunities, and if so, management should have no trouble delivering on its goal of growing sales to $21 billion in 2020 from an estimated $13 billion this year.

Celgene's widely used first-line multiple myeloma drug Revlimid has been a big reason the company's delivering significant top- and bottom-line growth. Originally approved for use in the second-line setting, the FDA approved it as a first-line drug in February 2015, and in February 2017, it also approved its use as maintenance therapy in multiple myeloma patients following stem-cell transplants to help prevent the cancer from progressing.

IMAGE SOURCE: GETTY IMAGES.

The company's success in expanding Revlimid's addressable market has caused Revlimid's sales to spike. In Q2, Revlimid revenue was $2.03 billion, up 19.6% year over year, and that has Celgene estimating $8 billion in revenue from the drug this year.

The strategy of expanding the use of its drugs to more patients, however, isn't limited to Revlimid. Management hopes to boost sales of its other drugs this way, too. For instance, studies are evaluating its third-line multiple myeloma drug, Pomalyst, as a second-line treatment. They're also exploring the use of its psoriasis drug Otezla in ulcerative colitis patients. And the company's pancreatic cancer drug, Abraxane, could someday be used to help treat patients with non-small-cell lung cancer and triple-negative breast cancer.

Given the company's track record with Revlimid, I think there's a good shot these trials pan out, and if so, then revenue and profit will march steadily higher.

Management may dominate multiple myeloma treatment, but it's not sitting on its laurels. Thanks to a slate of collaborations with emerging biotech companies, it has plenty of irons in the fire that could result in new drugs targeting a variety of cancer indications.

This week, the company's collaboration strategy took a big step forward when the FDA approved Idhifa, the first drug specifically OK'd to treat relapsed or refractory acute myeloid leukemia (AML) patients possessing a specific genetic mutation. Celgene co-developed Idhifa with Agios (NASDAQ:AGIO), and it won FDA approval only four short years after entering clinical trials.

Idhifa isn't likely to become a huge source of profits for Celgene because Celgene will share its success with Agios, but it could still rack up $100 million to $200 million in annual sales, or more, if it's eventually approved for first-line use. The two companies estimate that Idhifa's current addressable market is between 1,200 to 1,500 patients, and they've priced the drug at nearly $25,000 per month.

The company's also making headway on its other collaborations. Celgeneand partner Acceleron Pharma have completed of enrollment in phase 3 trials evaluating luspatercept in patients with lower-risk myelodysplastic syndromes and transfusion dependent beta-thalassemia. Results from those studies are anticipated in the middle of 2018.

Further back in the pipeline are intriguing chimeric antigen receptor T-cell drugs, too. Celgene's working with Juno Therapeutics on JCAR017, a non-Hodgkin lymphoma drug in early stage studies, and bluebird bio on bb2121, a multiple myeloma drug that's in phase 1 trials.

IMAGE SOURCE: GETTY IMAGES.

When Celgene launched psoriasis drug Otezla, it marked its first foray into treating autoimmune disorders. Now, Celgene's close to the finish line on yet another autoimmune-disease drug. It's targeting relapsing multiple sclerosis this time around, though.

Celgene spent over $7 billion buying Receptos to get its hands on the clinical-stage MS drug ozanimod, and based on ozanimod's success in phase 3 studies, that looks to have been money well spent.

The global MS market is worth over $22 billion, and about 40% of the market value belongs to oral MS drugs, including Gilenya, which generates sales of over $3 billion annually. Like Gilenya, ozanimod controls MS by inhibiting S1P to limit immune system responses. However, unlike Gilenya, ozanimod is more selective, and its selectivity may make it safer. During trials, ozanimod outperformed the MS drug Avonex without showing signs of the cardiovascular safety risks associated with Gilenya. If all goes well at the FDA, ozanimod could put a big dent in Gilenya's market share. It could also chip away at Tecfidera, another oral MS drug with nearly $4 billion in annual sales, depending on its label.

Celgene's also conducting a phase 3 trial of ozanimod in ulcerative colitis, and it expects enrollment in that trial to be complete this year. It's also got a phase 3 study of another drug, GED-0301, for use in Crohn's disease. Management expects enrollment in that trial to wrap up soon, too. Since these are blockbuster indications, a positive outcome in one or both of them could eventually be needle-moving.

In 2020, Celgene's wants to deliver $21 billion in sales and over $13 per share in earnings. Those figures represent a huge jump from the $13 billion and $7.25 in EPS that's forecast for 2017. Yet there's reason to think Celgene can meet or exceed those targets.Management based its long-term forecast on the drugs it currently has on the market, so if collaborations and R&D efforts yield new commercial-stage medicines, then Celgene should be able to deliver on its goal. In this respect, the company's best days may truly be yet to come.

Originally posted here:
3 Reasons the Best Is Yet to Come for Celgene - Motley Fool

(MENAFN Editorial) Essential Health Stem Cell is pleased to announce they offer regenerative therapy to patients looking to feel younger and be more active. These therapies use stem cells derived from umbilical cord samples and offer a non-surgical alternative to turning back the hands of time.

More individuals are looking for the safest, least invasive ways to restore the painless function and strength in their knees, shoulder, and other areas, theyve always wanted. While many people turn to chiropractic care and medical options, they dont have the same regenerative properties as stem cells offer. With the cutting-edge technological advances in extracting stem cells from umbilical cord blood samples, Essential Health Stem Cell strives to give patients access to the latest treatments for the best possible results.

Patients who undergo these stem cell therapies through Essential Health Stem Cell will be able to enjoy their regular daily activities right away, unlike with other surgical options. Stem cell therapy is painless, risk free and has no negative short or long-term effects. Their professional staff strives to give each of their patients the quality care they require to get the results theyre looking for.

Anyone interested in learning about these regenerative therapies can find out more by visiting the Essential Health Stem Cell website or by calling 1-336-230-2255.

About Essential Health Stem Cell : Essential Health Stem Cell is a medical provider that offers stem cell therapies designed to regenerate the body and help individuals live a more youthful lifestyle. Their regenerative therapies are designed to help patients achieve their health goals with less risk than many of the surgical options. These treatments are cutting-edge and dont have the same negative effects as other treatments.

For more information visit us our website http://www.ehstemcell.com.

Company : Essential Health Stem Cell Contact : David Gibson Address : 526 North Elam Avenue, #101, Greensboro, NC 27403 Phone : 1-336-230-2255 Email : Website : http://www.ehstemcell.com

MENAFN3107201700703262ID1095675254

Visit link:
Essential Health Stem Cell Offers Regenerative Therapy - MENAFN.COM

Conference Series Ltdinvites all the members of Biological Sciences family, from all over the world to join and share research at the10th World Congress on Stem Cell and Biobankingduring 23th& 24thOctober, 2017 at Osaka, Japan, which includes prompt keynote presentations, plenary talks, oral talks, poster presentations and exhibitions.

Theme: Accelerating the Innovative Research &Technology in Stem Cell & Biobanking

Stem Cell Convention 2017aims in proclaim knowledge and share new ideas amongest the professionals, industrialists and students from research area of Stem Cells and Biobanking to share their research experiences and indulge in interactive discussions at the event. This scientific gathering guarantees that offering the thoughts and ideas will enable and secure you the theme Accelerating the Innovative Research &Technology in Stem Cell & Biobanking. Biobanking is the latest trending technology in many fields. The current era fully rolled out with many new Stem cells and Biobanking technologies. In such case more research centres and Hospitals were newly introduced within market which obviously shows the market growth of stem cells and Biobanking techniques. While analyzing the revenue growth of stem cells research, it highly developed from $150 billion USD to $250 billion USD since from 2010-2015. And the annual growth percentage increases from 20-55 percentages.

Track-1

Stem Cells Biology

Stem cellsare undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells:embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells andprogenitor cellsact as a repair system for the body, replenishingadult tissues. In a developing embryo, stem cells can differentiate into all the specialized cellsectoderm, endoderm and mesoderm (see induced pluripotent stem cells)but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.Umbilical cord cells are also included in this Stem Cell Research.

Related Stem Cell Convention | Stem Cell Conferences | Biobanking Congress | Stem Cell Banking|Cord Blood Stem Cell Research|

7th Annual Conference on Stem Cell and Regenerative Medicine ,Aug 4-5, 2016, Manchester, UK; 2nd International Conference on Antibodies,July 14-15, 2016 ,Philadelphia, USA; 2nd International Conference on Innate Immunity,July 21-22, 2016 ,Berlin, Germany; 2nd International Congress on Neuroimmunology ,March 31-April 02, 2016, Atlanta, USA; International Conference on Cancer Immunology ,July 28-30, 2016 ,Melbourne, Australia.

Stem cells technologyis a rapidly developing field that combines the efforts of cell biologists,geneticists, and clinicians and offers hope of effective treatment for a variety of malignant and non-malignant diseases. Stem cells are defined astotipotent progenitor cellscapable of self-renewal and multilineage differentiation. Stem Cell s technologysurvive well and show stable division in culture, making them ideal targets for in vitro manipulation. Although early research has focused on hematopoietic stem cells, stem cells have also been recognised in other sites. Research into solid tissue stem cells has not made the same progress as that on hematopoietic stem cells. This is due to the difficulty of reproducing the necessary and precise three dimensional arrangements and tight cell-cell and cell-extracellular matrix interactions that exist in solid organs. However, the ability of tissue stem cells to integrate into the tissue cytoarchitecture under the control of the host microenvironment and developmental cues makes them ideal for cell replacement therapy. Some of the methods of Stem Cells technology include Cord Stem Cell Transplantation, Allogeneic stem cell transplantation.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

8th World Congress on Stem Cell Research ,March 20-22, 2017 ,Orlando, USA;International Conference on Cancer Immunology ,July 28-30, 2016 ,Melbourne, Australia; 5th International Conference on Immunology ,October 24-26, 2016 ,Chicago, USA; Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, Mar 610 2016, Whistler, Canada; Systems Immunology: From Molecular Networks to Human Biology, Jan 1014 2016, Big Sky, USA.

Track-3

Stem Cells Therapy Research

Stem cells therapyis the use of stem cells to treat or prevent a disease or condition.Bone marrow transplantis the most widely used stem-cells therapy, but some therapies derived from umbilical cord blood are also in use. Research is underway to develop various sources forstem cells, and to apply stem-cells treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions.Cord blood stem cells therapy is highly recommended at the time of delivery to save the umbilical cord of the child to resolve any future health conditions. Umbilical cord stem cells research has more scope to resolve the issues caused due to DNA changes.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thInternationalConference on Plant Genomics,July 14-15, 2016 ,Brisbane, Australia; 8thWorld Congress on Stem Cell Research,March 20-22, 2017 ,Orlando, USA; 7thAnnual Conference on Stem Cell and Regenerative Medicine,Aug 4-5, 2016, Manchester, UK; 2ndInternationalConference on Tissue preservation and Biobanking,September 12-13, 2016 ,Philadelphia, USA;World Congress on Human Genetics,October 31- November 02, 2016 ,Valencia, Spain.

Track-4

Epigenetics

Epigeneticsis the study of potentially heritable changes in gene expression (active versus inactive genes) that does not involve changes to the underlyingDNA sequence a change in phenotype without a change in genotype which in turn affects how cells read the genes. Epigenetic change is a regular and natural occurrence but can also be influenced by several factors including age, the environment/lifestyle, and disease state. Epigenetic modifications can manifest as commonly as the manner in which cells terminally differentiate to end up as skin cells, liver cells, brain cells, etc. Or, epigenetic change can have more damaging effects that can result in diseases like cancer. At least three systems includingDNA methylation, histone modification and non-coding RNA (ncRNA)-associated gene silencing are currently considered to initiate and sustain epigenetic change. New and ongoing research is continuously uncovering the role of epigenetics in a variety ofhuman disordersand fatal diseases.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Next Generation Sequencing,July 21-22, 2016 ,Berlin, Germany; 5thInternationalConference on Computational Systems Biology,August 22-23, 2016 ,Philadelphia, USA; 7thInternationalConference on Bioinformatics,October 27-28, 2016 ,Chicago, USA; InternationalConference on Synthetic Biology,September 28-30, 2015 ,Houston, USA; 4thInternationalConference on Integrative Biology,July 18-20, 2016 ,Berlin, Germany.

Track-5

Stem cells apoptosis and signal transduction

Self-renewal and proliferation ofstem cellspopulation is controlled, in part, by induction of apoptosis. The number of stem cells is therefore a balance between those lost to differentiation / apoptosis and those gained through proliferation.Apoptosisof stem cells is believed to be a dynamic process which changes in response to environmental conditions. For example, the release of stem cells factor inhibits apoptosis following spinal cord injury, presumably in an attempt to promotetissue repair. Dysregulation of apoptosis instem cellsis believed to underlie somecancer pathologies, where apoptotic resistance results in uncontrolled growth (i.e. glioblastoma). Controlling apoptosis is also an important focus for studies ofstem cells transplantation, where inhibition may increase the survival of grafted cells during replacement therapy. Harnessing the full therapeutic potential of stem cells will require full elucidation of the signal transduction cascades for proliferation, differentiation, and apoptosis.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

7thInternationalConference on Bioinformatics,October 27-28, 2016 ,Chicago, USA; InternationalConference on Synthetic Biology,September 28-30, 2015 ,Houston, USA; 7thAnnual Conference on Stem Cell and Regenerative Medicine,Aug 4-5, 2016, Manchester, UK; 4thInternationalConference on Integrative Biology,July 18-20, 2016 ,Berlin, Germany; 1stInternationalConference on Pharmaceutical Bioinformatics,Jan 2426 2016, Pattaya, Thailand.

Trcak-6

Regenerative medicine

Regenerative medicineis the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. Regenerative medicine includes the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Restorative Medicine,October 24-26, 2016 ,Chicago, USA; 3rdWorld Congress onHepatitis and Liver Diseases,October 17-19, 2016 Dubai, UAE; InternationalConference on Molecular Biology,October 13-15, 2016 ,Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking, September12-13, 2016 ,Philadelphia USA; 26thEuropean Congress ofClinical Microbiology, April 912 2016, Istanbul, Turkey;Conference onCell Growth and Regeneration, Jan 1014 2016, Breckenridge, USA.

Track-7

Bio-banks

Biobanksplay a crucial role in biomedical research. The wide array ofbio specimens(including blood, saliva, plasma, and purified DNA) maintained inbiobankscan be described as libraries of the human organism. They are carefully characterized to determine the general and unique features of the continuous cell line and the absence or presence of contaminants, therefore establishing a fundamental understanding about the raw material from which the biological product is being derived and maintained.Biobankscatalog specimens using genetic and other traits, such as age, gender, blood type, and ethnicity. Some samples are also categorized according to environmental factors, such as whether the donor had been exposed to radiation, asbestos, or some other substance that can affecthuman genes.In Biobank Category the most popular biobank projects includes cord blood banking, banking stem cells, baby cord blood banking.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

8thWorld Congress on Stem Cell Research,March 20-22, 2017 ,Orlando, USA; 5thInternationalConference onCell and Gene Therapy,May 19-21, 2016 ,San Antonio, USA; 7thAnnual Conference on Stem Cell and Regenerative Medicine,Aug 4-5, 2016 ,Manchester, UK; InternationalConference on Restorative Medicine,October 24-26, 2016 ,Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE.

Track-8

Stem cells biomarkers

Bio markeris a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A bio marker may be used to see how well the body responds to a treatment for a disease or condition.

In cancer research and medicine, bio markers are used in three primary ways:

To help diagnose conditions, as in the case of identifying early stage cancers (Diagnostic)

To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)

To predict how well a patient will respond to treatment (Predictive).

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Genetic Counseling and Genomic Medicine,August 11-12, 2016 ,Birmingham, UK;World Congress on Human Genetics,October 31- November 02, 2016 ,Valencia, Spain; InternationalConference on Molecular Biology,October 13-15, 2016 ,Dubai, UAE; 3rdInternationalConference on Genomics & Pharmacogenomics,September 21-23, 2015 ,San Antonio, USA; EuropeanConference on Genomics and Personalized Medicine ,April 25-27, 2016 ,Valencia, Spain.

Track-9

Cells & Organ Regeneration

Regenerationmeans the regrowth of a damaged or missing organ part from the remaining tissue. As adults, humans can regenerate some organs, such as the liver. If part of the liver is lost by disease or injury, the liver grows back to its original size, though not its original shape. And our skin is constantly being renewed and repaired. Unfortunately many other human tissues dont regenerate, and a goal inregenerative medicineis to find ways to kick-start tissue regeneration in the body, or to engineerreplacement tissues.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases,May 16-18, 2016 ,San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,Oct 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Track-10

Fertility biobanks

Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into howcanceraffects reproductive health and preservation options are growing, sparked in part by the increase in the survival rate of cancer patients. The main methods of fertility preservation are ovarian protection by GnRH agonists, cryopreservation of ovarian tissue, eggs or sperm, or of embryos afterin vitro fertilization. The patient may also choose to use egg or sperm from a donor by third party reproduction rather than having biological children.

Related Stem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases,May 16-18, 2016 ,San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,October 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology ,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Track-11

Biobank Ethics

Ethical issues are commonly present in many aspects ofBiobanking. The fact that Biobanks deal with human samples, invading an individual autonomy or limiting self-control, provokes a number of ethical issues. Who is actually competent to give informed consent and donate a sample? When individuals donate part of their body to abiobank, how is that human sample processed? Who is the owner of the sample? Who should decide how it should be used? Who has the right to know individual results of research? These and many more ethical dilemmas exist in the ethical framework of biobanks. With the recent rapid developments in Biobanking, all of these issues are magnified with plenty of further new questions continuously arising. Ethical framework has been the most controversial issue in the domain of biobanking. Thus, it is not surprising that there is a substantial literature focusing on ethical dilemmas in biobanking, such as informed consent, privacy, protection, and returning of results to participants. For many years, researchers at CRB have provided constructive advice on how to deal with ethical aspects of research usinghuman tissuematerial and personal data. For more than 80 years tissue has been derived from human bodies, stored, distributed and used for therapeutic, educational, forensic and research purposes as part of healthcare routine in most western countries.

American Society forBioethicsand Humanities Houston, USA, Association of Bioethics World Congress Edinburgh, UK, Oxford Global Health and Bioethics International Conference Oxford shire, UK, CFP: Global Forum on Bioethics in Research Foundation Merieux, France, Hands On Biobanks 2016 conference Vienna, Austria, Global Biobanking London, UK, TheBiomarker ConferenceOrlando, Florida USA, ART World Congress Symposium on Safe and Efficient IVF New York City, United States, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases,May 16-18, 2016 San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,October 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Track-12

Market Analysis in Biobanking

The globalbiopreservationmarket is expected to reach USD 3,731.03 Million by 2020 from USD 2,150.48 Million in 2015, growing at a CAGR of 11.65% between 2015 and 2020. Biopreservation is used to ensure the stability, quality and purity ofbiospecimens. With a CAGR of 23.7%, global market value for cryopreservation equipment used instem cellsindustry is anticipated to worth US$2.2 billion by 2015. On a global scale, North America accounts for nearly 35% of the market and will likely witness a higher growth rate in the upcoming years, in comparison with Asia-Pacific. While US accounts for the highest share of the global market value on a country basis, India and China surpasses the US in terms of growth rate anticipated in the near future. As per our analysis, freezers represent more than half of thecryopreservationequipment market value while Cyropreservative reagents stand for a share of close to 20%. The global biopreservation market is poised for rapid growth between 2015 and 2020. The drivers include increasing healthcare expenditure, growing demand for preserving new-borns stem cells, increasing R&D spending on research, and increasing adoption ofregenerative medicine.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Case Reports,March 31-April 02, 2016 ,Valencia, Spain; 2nd International Meeting onClinical Case Reports,April 18-20, 2016 ,Dubai, UAE; 3rd Experts Meeting onMedical Case Reports,May 09-11, 2016 ,New Orleans, Louisiana, USA; 12thEuro BiotechnologyCongress,November 7-9, 2016 ,Alicante, Spain; 2nd InternationalConference onTissue preservation and Biobanking,September 12-13, 2016 ,Philadelphia, USA.

Track-13

Next Generation Biobanking

Biorepositoriesprovide a resource for researchers to increase understanding of complex diseases. Studies such as the Lung Genomics Research Consortium (LGRC), a two-year project launched in October 2009, are going a step further than standardbiobanking practicesand characterizing the samples with their molecular makeup. The molecular data can then be mined along with the clinical data. Led by National Jewish Health and funded by the National Heart, Lung and Blood Institute, a division of the National Institutes of Health (NIH), the LGRC project consists of five institutions, including Dana-Farber Cancer Institute. Collaborators in the project work with samples banked at theLung Tissue ResearchConsortium (LTRC), which houses tissue samples and blood from lung disease sufferers, primarily chronic obstructive pulmonary disease (COPD), along with a rich set of clinical data from patients.

Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, HandsOn Biobanks 2016 conference Vienna, Austria, American Society forBioethicsand Humanities Houston, USA, Craniofacial Morphogenesis &Tissue RegenerationVentura, CA, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Phacilitate Cell &Gene TherapyWorld Washington D.C., USA, Notch Signaling in Development, Regeneration & Disease Gordon Research Conference Lewiston, ME, USA.

The biobanking market is poised for explosive growth if it can overcome the challenges of an adolescent industry. According to an August 2012 Infiniti Research report titled Global Biobanking Market 2011-2015, the biobanking market will increase 30 per cent from 2011 to 2015 to nearly $183 billion. Growth is being driven by an increase in populationgeneticsstudies, personalized medicine, and the use of genetic information in food safety, forensics, and disease surveillance.

Related Stem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases, May 16-18, 2016 San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,October 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology ,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Follow this link:
Stem Cell and Biobanking - Stem Cell Conferences

Lisa Rathke, AP Images

Media portrayals of campus controversies, as when students shouted down Charles Murray at Middlebury College earlier this year, contribute to negative views of colleges among Republicans.

A majority of Republicans and right-leaning independents think higher education has a negative effect on the country, according to a new study released by the Pew Research Center on Monday. The same study has found a consistent increase in distrust of colleges and universities since 2010, when negative perceptions among Republicans was measured at 32 percent. That number now stands at 58 percent.

The divides between folks on the left and folks on the right are getting more serious.

By comparison, 72 percent of Democrats or left-leaning Independents in the study said colleges and universities have a positive impact on the United States.

In an increasingly polarized culture, the drastic shift is the latest piece of evidence that institutions of higher education along with labor unions, banks, churches, and the news media have been plunged headfirst into a hyperpartisan war.

That war started a long time ago, though its intensified lately. "The divides between folks on the left and folks on the right are getting more serious," said Neil L. Gross, a professor of sociology at Colby College and author of the book, Why Are Professors Liberal and Why Do Conservatives Care? "I dont think theres any evidence that its going to subside anytime soon."

For years, higher education has been viewed favorably by liberals and less so by conservatives, Mr. Gross said, but political controversies in the past year have drawn attention and increased the negative perception. Protests and incidents of speakers being actively opposed or threatened by students are widely reported, he said, and are often one of the few ways in which the general population encounters college campuses.

"Its not surprising how people hold onto publicly available narratives on college campuses," he said. "I think its understandable, though regrettable."

David Hopkins, an associate professor at Boston College and co-author of Asymmetric Politics: Ideological Republicans and Group Interest Democrats, said the negative view of colleges and universities is an expectable manifestation of this increase in coverage of college campuses. For instance, the website Campus Reform is a steady purveyor of perceived liberal bias on college campuses, and such controversies are often featured on the Fox News program Tucker Carlson Tonight.

"This has become a major subject of conservative coverage of contemporary politics and contemporary campus life," Mr. Hopkins said. "Its no surprise an echo of that coverage would start to show up in public opinion on the right."

That reporting, Mr. Hopkins said, has only exacerbated an existing distrust of colleges and universities among conservative thinkers.

The conservative critique of the social sciences in the mid- and late-1900s, he said, has grown to include the hard sciences in the last 20 years, largely among subjects like stem-cell research, climate change, and evolution.

A change in the demographics of both parties has also influenced the mistrust of colleges, he said. Whereas 50 years ago, the best predictor of conservative alignment was a high level of education, Mr. Hopkins said, "the popular base of the Republican party is less and less white-collar professionals and is more and more white working-class non-college-educated voters." Whether or not someone had a college degree was considered by many observers to be the most compelling predictor of whether they voted Republican or Democrat in the last presidential election.

This change has given rise to a perception by conservatives of liberal elitism an impression that can frame institutions of higher education as inherently partisan, according to Sean J. Westwood, an assistant professor of social science at Dartmouth College and a co-author of the recent study "Fear and Loathing Across Party Lines: New Evidence on Group Polarization."

Colleges are simply seen as a production facility for Democratic beliefs and Democratic ideology.

"There is a perception that Democratic elites are well-educated and Republicans are more of the common man," Mr. Westwood said. "Colleges are simply seen as a production facility for Democratic beliefs and Democratic ideology."

In the Pew Research Centers study, distrust of colleges was strongest in the highest income bracket and the oldest age group, with approval levels of just 31 percent among respondents whose family income exceeds $75,000 a year and 27 percent among those older than 65.

Favor for higher education was highest among Republicans who are younger than 29 (52 percent) and those who have not completed a college degree (37 percent).

Outside of party beliefs, Mr. Gross said, higher education is not a big part of an average persons life. If thats true, he said, then many of the answers given on such polls may not come from personal experience. "Theyre very likely just filling in the blanks from their partisan knowledge and opinions," Mr. Gross said. "Part of what it means to be a conservative and a Republican is to voice opposition to liberal tendencies on college campuses."

"People are essentially taking cues from party leaders and conservative media," he said, "about opinions they are supposed to have."

Read this article:
Most Republicans Think Colleges Are Bad for the Country. Why ... - The Chronicle of Higher Education

Stem cell therapy: the next wave in regenerative medicine?

All it involved was a quick injection no different, really, than a flu shot.

A few weeks later, Bill Ambrose realized hed become significantly less reliant on taking Aleve for knee pain, and he was re-learning how to walk without shuffling his feet.

Surgery, it turned out, might not be necessary after all.

Last November, Ambrose scheduled knee surgery to alleviate discomfort in his knees caused by what orthopedic doctors called true bone-on-bone at the joint. But for one reason or another, he kept missing pre-surgery and the surgery never happened.

The next month, Ambrose met with Dr. Bill Nolan, of Cherry Street Health Group, to discuss advertising space in the Danvers Herald.

For the purpose of full disclosure, Ambrose is an employee of Gatehouse Media Company, and he works in the advertising department for Wicked Local, the local branch of GHM newspapers.

After Nolans ads ran inthe Jan. 5issue of the Herald, Ambrose said he reached out to Nolan again. This time, for himself.

Nolans practice offered a solution to his knee pain an alternative to knee surgery he had never considered before: stem cell therapy.

Essentially, the solutionCherry StreetHealth Group offered was an injection of amniotic fluid into Ambrose's knee joint. The stem cells and other growth factorsin the fluid would allow for the regeneration of the cartilage at the joint.

I became interested so I decided to go ahead with it, Ambrose said.

He brought in scans to show Nolan, who said, contrary to what orthopedic doctors had told him, he didnt have true bone on bone. There was still a small space between the bones.

I decided to have one leg done and my knee started getting much better, he said.

Satisfied with the results of the first injection, Ambrose decided to get his left knee done in April.

I still experience some pain in [the left knee], but I get up in the morning and theres very little pain at all, he said in an interview a few weeks following the appointment.

The stem cell option

In the U.S., there are three ways that stem cells are used, Nolan said. Theyre either taken from bone marrow, fat cells, or the amniotic membrane of a healthy c-section from a consenting woman.

When stem cellsare injected into the body,they're expected to increase space at the joint, rebuild cartilage, and ultimately, provide more stability in the joint. As many as 570 businesses across the country advertise some kind of stem cell therapy, according to a 2016 paper.

Stem cell therapy is not necessarily a new discovery, but it is relatively recent in the world of regenerative medicine.Stem cells were first used as much as century ago, first for eye procedures and as filler for the spinal cord, according to Regenexx, which claims to have pioneered orthopedic stem cell treatments in 2005.

Adult stem cells are retrieved directly from the patient, either frombone marrow or fat cells,and concentrated beforeits reinjectedinto the patient's site of pain.

In the case of amniotic fluid therapy,amniotic fluid, which contains stem cells and other growth factors, is injected into the site. These cellshave been shown to "expand extensively" and show "high renewal capacity,"according to research published in the National Library of Medicine.

We know that as you age, your stem cell count decreases,Nolan said, explaining the benefit of using cells from the amniotic membrane. We know that when we get it from the amniotic membrane, theres a large amount of stem cells that are present. From the amniotic membrane, there are no antibodies or antigens, so its safe for anyone to get.

At Cherry Street Health Group, theproduct usedis produced by General Surgical and distributed by RegenOMedix, according to Nolan.The product, which is called ReGen Anu RHEO, is American Tissue Bank approved and FDA cleared.

RHEO is marketed as "a human tissue allograft derived from placental tissue; amniotic membrane and amniotic fluid."Its a"powerful combination" of amniotic fluid and mesencymal stem cells, which are known to differentiate into a variety of cell types, according to RegenOMedix.It also contains growth factor proteins andis "rich" in other necessary components for tissue regeneration.

The product is non-steroidal and comes with no side effects, and the company says no adverse events have been recorded using the product.

Nolan said stem cell therapy has been offered as a treatmentat Cherry Street since 2016.

Across the U.S., there are as many as 56 businesses marketing some form of amniotic stem cellsto its consumers, according to the same paper.

At Rush University Medical Center in Chicago, for example, orthopedic surgeon Adam Yanke enrolled one of his patients into an experimental amniotic cell therapy treatment program. The woman, a 65-year-old suffering from osteoarthritis in both knees, told reporters the injections were "by far the most effective pain treatment" she had tried, and so farthat relief has lasted up to a year.

But while the use of amniotic fluid therapyas a regenerative medicine is becoming increasingly popular throughout the U.S.,the use of amniotic stemcellsdoesn't comewithout concern from some within the community.

Dr. Chris Centeno, who specializes in regenerative medicine andthe clinical use of adult stem cells, has blogged numerous times for Regenexx on the "scam" of using amniotic stem cells most recently in sharply worded post on May 22.

"Regrettably, we have an epidemic on our hands that began when sales reps began telling medical providers thattheir dead amniotic and cord tissues had loads of live cells on it," he wrote.

Nolan said he was familiar with Centeno's posts.

"A lot of the stem cell stuff is new," he said. "Some of the products out there ... They were doing testing on them and not finding cells."

Cherry Street Health Group has treatedabout 50patients with this form of regenerative medicine and had significant success, according to Nolan. Although Nolan owns the health group on Cherry Street in Danvers, the stem cell treatments are provided under the medical practice of Dr. Pat Scanlan.

Weve had really, really amazing success, Nolan said. Weve had over 95 percent success of all the patients weve had in the office. Its been a game changer from a practice standpoint.

The "worst thing" that could happen is there might not be any regeneration, he explained.

"You might get pain relief, but no regeneration," Nolan said. "But from what weve seen, there have been no negative side effects."

At Cherry Street, knees are the most commonly treated joints, followed by hips, shoulders and the lower back. The cervical spine is the least common.

"I hesitated on the surgery, and I'm gladI did," Ambrose said. "Even if[the stem cells]don't do any more than what they've done, its been well worth it."

Patients who do present with true bone on bone, however, are not candidates for this form of therapy, Nolan said.

The cost comparison

At Cherry Street Health Group, the cost of the injection comes toroughly $4,000 per knee, a cost that isn't covered by insurance. By comparison, health-care providers often charge insurers more than $18,000 for knee replacement surgeries in the Boston area, according to a report by the Blue Cross and Blue Shield Association.

The report, however, doesn't account for what the patient actually pays.

Nolan said when other factors of post-op are considered time off of work, rehabilitation time and cost the out-of-pocketcost for surgery compared to stem cell treatment is comparable.

"When you really boil it down, it can be the same or, in a lot of cases, a savings," he said.

Ambrose said it "boggles his mind" that more people don't choose this treatment over surgery.

"Why would you spend $40,000 on a car and not want to spend $4,000 on a knee?," he said."Its crazy. Yes, its out of pocket. So what? We buy a lot of stuff we dont need, and then for something like this, something that people, if they do it, theyll be glad they did it. Its just hard to convince them to do it."

In arecent report in STAT news, a health news start up of the Boston Globe, a study of orthopedic procedures in the U.S. suggested an estimated one-third of knee replacement surgeries are inappropriate. More than 640,000 of these surgeries are performed each year, making for a $10 billion dollar industry in knee surgery.

The study said that evidence isn't limited to just knee surgeries.

"There's a lot that needs to change when we look at health care in general,"Nolan said. "It's really no surprise that something like doing this regenerative medicine is going to take time for it to really take off."

Continue reading here:
Danvers health group offers alternative solution to surgery - Wicked Local Danvers

Dr. Lewis A. Chodosh is a physician-scientist who received a BS in Molecular Biophysics and Biochemistry from Yale University, and MD from Harvard Medical School, and a PhD. in Biochemistry from M.I.T. in the laboratory of Dr. Phillip Sharp.He performed his clinical training in Internal Medicine and Endocrinology at the Massachusetts General Hospital, after which he was a postdoctoral research fellow with Dr. Philip Leder at Harvard Medical School.Dr. Chodosh joined the faculty of the University of Pennsylvania in 1994, where he is currently a Professor in the Departments of Cancer Biology, Cell & Developmental Biology, and Medicine. He serves as Chairman of the Department of Cancer Biology, Associate Director for Basic Science of the Abramson Cancer Center, and Director of Cancer Genetics for the Abramson Family Cancer Research Institute at the University of Pennsylvania. Additionally, heis on the scientific advisory board for the Harvard Nurses' Health Studies I and II.

Dr. Chodosh's research focuses on genetic, genomic and molecular approaches to understanding breast cancer susceptibility and pathogenesis.

Continue reading here:
Breast Cancer Research | Home page